# China NMPA Drug Inspection - Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. - Akebia

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-huayun-traditional-chinese-medicine-pieces-co-ltd/6f1ff175-73a9-45df-9a9b-ada0ff1fefaf/
Source feed: China

> China NMPA drug inspection for Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. published December 08, 2020. Drug: Akebia. On December 8, 2020, the Shanxi Provincial Drug Administration announced that seven batches of drugs failed to meet qual

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shanxi Provincial Drug Administration Regarding 7 Batches of Drugs That Failed to Meet Regulations
- Company Name: Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-12-08
- Drug Name: Akebia
- Inspection Finding: The properties did not meet the requirements.
- Action Taken: The relevant enterprises and units have taken risk control measures such as suspending sales and use and recalling products, and have been investigated and dealt with in accordance with the law.
- Summary: On December 8, 2020, the Shanxi Provincial Drug Administration announced that seven batches of drugs failed to meet quality standards during routine annual sampling inspections. The inspections covered various production, distribution, and healthcare facilities to ensure public medication safety. Several manufacturers were identified for non-compliance, including Hebei Runhua Pharmaceutical Co., Ltd., Shanxi Lifeng Huarui Pharmaceutical Co., Ltd., Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd., Jiuquan Peifeng Traditional Chinese Medicine Ecological Planting and Processing Co., Ltd., Anhui Wugeng Traditional Chinese Medicine Pieces Co., Ltd., and Anhui Runbang Traditional Chinese Medicine Pieces Co., Ltd. The main issues identified involved moisture content, which can degrade drug quality; dissolution rates, which affect how effectively the body absorbs the medicine; and failures in appearance and ash content tests, which suggest issues with purity or processing techniques for traditional Chinese medicines. Under the regulatory oversight of the National Medical Products Administration (NMPA), the provincial authorities have launched formal investigations into these violations. The involved companies and pharmacies are required to take immediate risk control measures, including the suspension of all sales and use of the substandard batches and the initiation of product recalls to protect consumers.

Company: https://www.globalkeysolutions.net/companies/bozhou-huayun-traditional-chinese-medicine-pieces-co-ltd/7d6c21b3-e71c-4ee7-ba0e-c295534ea1a4/